DDInter1459 DDInter1376
Phenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. It is available in combination products that also contain other analgesics and antitussives such as acetaminophen. Phenyltoloxamine citrate is the more common salt form that acts as an active ingredient in pharmaceutical products and promotes hay fever relief via reversing the effects of histamine. Phenyltoloxamine acts as an adjuvant analgesic, which augments the analgesic effect of acetaminophen. It also potentiates the effects of other drugs, such as codeine and codeine derivatives. Although phenyltoloxamine's ability to potentiate the effects of analgesics may be explained in part by its chemical nature as a first-generation H1 antihistamine that is capable of crossing the blood-brain
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Phenyltoloxamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hyaluronidase
Phenyltoloxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alimemazine
Phenyltoloxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentoxyverine
Phenyltoloxamine {u} may lead to a major life threatening interaction when taken with {v} Potassium chloride
Phenyltoloxamine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Phenyltoloxamine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Phenyltoloxamine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Phenyltoloxamine may lead to a major life threatening interaction when taken with Potassium chloride